Nectar Lifescience Ltd Financials
Company Logo

Nectar Lifescience Ltd Financial Statement

Nectar Lifescience Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue359.85
Operating Expense319.50
Net Profit2.97
Net Profit Margin0.83
Earning Per Share0.13
EBIDTA38.41
Effective Tax RateTBA

Nectar Lifescience Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual1,684.09
Operating Expenses Annual1,532.53
Operating Profit Annual166.14
Interest Annual87.14
Depreciation60.72
Net Profit Annual5.00
Tax Annual13.27

Nectar Lifescience Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning17.57
Cash Flow from Operations224.69
Cash Flow from Investing-17.03
Cash Flow from Financing-205.44
Cash Flow at the End19.80

Nectar Lifescience Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)8.63
PBIT Margin (%)5.47
PBT Margin (%)5.41
Net PROFIT Margin (%)0.26
Return On Networth / Equity (%)0.47
Return On Networth /Employed (%)5.96
Return On Assets (%)0.28
Total Debt / Equity (X)0.65
Asset Turnover Ratio (%)1.09

Nectar Lifescience Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual642.71
Total Current Assets Annual1,283.83
Non Current Assets Annual907.23
Total Shareholders Funds Annual1,069.25
Total Assets Annual2,191.06

Nectar Lifescience Ltd Earning Calls

EPS (INR)

Expected

0.13

Reported

0.13

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Sep 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Oct 15, 2024, Nectar Lifescience Ltd has a market capitalization of 675.25 Cr. Value Research classifies it as a Small-Cap company.
No, Nectar Lifescience Ltd is not debt-free with a debt-to-equity ratio of 0.59.
In FY 2023 , Nectar Lifescience Ltd recorded a total revenue of approximately 1,684.09 Cr marking a significant milestone in the company's financial performance.
Nectar Lifescience Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.0% annually, respectively..
Nectar Lifescience Ltd's current PE ratio is 135.05.
Nectar Lifescience Ltd's ROCE averaged 4.7% from the FY ending March 2022 to 2024, with a median of 5.8%. It peaked at 6.2% in March 2024, reflecting strong capital efficiency over the period..
Nectar Lifescience Ltd's latest EBIT is Rs. 105.42 Cr, surpassing the average EBIT of Rs. 85.79 Cr over the 5 years..